Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis

Journal of the Formosan Medical Association

Volumn 109, Issue 12, 2010, Pages 923-927

  Hsu, Han Lin ^a   Bai, Kuan Jen ^a   Chiang, Yi Chun ^a,b   Lin, Shian Jiun ^a   Yu, Ming Chih ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis; Multidrug resistant tuberculosis; Prothionamide

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSERINE; ETHAMBUTOL; HEPATITIS A ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; RIFATER; STREPTOMYCIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS; HUMAN; LIVER FUNCTION; MALE; MONITORING; MULTIDRUG RESISTANT TUBERCULOSIS; RECURRENT DISEASE;

EID: 79951889240     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60141-6     Document Type: Article

References (13)

1. Yu MC, Wu MH, Jou R. Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis 2008;14:849-50.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
3. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007;11:1314-20.
4. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7.
5. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:648-55.
6. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-5.
7. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8:1382-4.
8. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002;359:1980-9.
9. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
10. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117:744-51.
11. Anonymous. A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle 1968;49: 125-35.
12. Somner AR, Brace AA. Changes in serum transaminase due to prothionamide. Tubercle 1967;48:137-43.
13. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.